Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Posts 2 Percent Revenue Growth for Q3

NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported its third-quarter sales grew 2 percent year over year on soft demand from its research end markets and a 6 percent negative effect from foreign currency exchange.

The St. Louis-based chemicals and research products firm reported total sales of $639 million for the three months ended Sept. 30 compared to $626 million in sales for the third quarter of 2011. It fell short of Wall Street's consensus estimate of $657.6 million.

Sales for its Research Chemicals unit dropped 4 percent to $428 million from $446 million. On an organic basis, sales for the unit were up 1 percent.

Sales for the firm's SAFC business grew 17 percent to $211 million from $180 million. On an organic basis, sales for the unit were up 5 percent year over year.

"While we continue to experience soft demand in our Research business, our end markets have remained relatively stable from second quarter levels," Sigma-Aldrich President and CEO Rakesh Sachdev said in a statement. "We believe our recent initiatives, including new product launches and expansion in emerging markets, have set us up for improved performance in the coming quarters."

Sigma-Aldrich posted a profit of $112 million, or $.92 per share, compared to net income of $117 million, or $.95 per share, for Q3 2011. On an adjusted basis, EPS was $.94, matching analysts' consensus estimate.

The firm's R&D spending for the quarter was down around 6 percent to $17 million from $18 million, and its SG&A expenses declined 3 percent to $147 million from $152 million.

Sigma-Aldrich finished the quarter with $589 million in cash and cash equivalents.

The company said that it expects to report full-year 2012 organic revenue growth of around 3 percent, in line with its prior guidance of low- to mid-single digits. Foreign exchange rates are expected to reduce reportable sales for the year by around 3 percent. Its adjusted EPS is expected to between $3.80 and $3.90.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.